tiprankstipranks
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
PremiumPress ReleasesFavorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
1M ago
OncoCyte reports Q1 EPS ($1.13), consensus (67c)
PremiumThe Fly
OncoCyte reports Q1 EPS ($1.13), consensus (67c)
2M ago
OncoCyte files to sell 5.42M shares of common stock for holders
PremiumThe Fly
OncoCyte files to sell 5.42M shares of common stock for holders
2M ago
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
PremiumPress ReleasesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
3M ago
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
PremiumPress Releases
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
3M ago
OncoCyte, BioRad to partner on global launch of GraftAssure assay
PremiumThe Fly
OncoCyte, BioRad to partner on global launch of GraftAssure assay
3M ago
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
PremiumPress ReleasesOncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
7M ago
OncoCyte begins FDA submissions process for VitaGraft transplant assays
PremiumThe Fly
OncoCyte begins FDA submissions process for VitaGraft transplant assays
7M ago
Oncocyte Reports Third Quarter 2023 Financial Results
PremiumPress Releases
Oncocyte Reports Third Quarter 2023 Financial Results
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100